China Approves MSD's Welireg (belzutifan) for VHL-Associated Tumors
核心洞察
China's NMPA has approved MSD's Welireg (belzutifan) for treating specific von Hippel-Lindau (VHL) disease-associated tumors in adults, offering a non-surgical option.
The approval is based on Phase II LITESPARK-004 trial results, demonstrating significant objective response rates in renal cell carcinoma (搜索), CNS hemangioblastomas, and pNET.
Welireg, a hypoxia-inducible factor-2 alpha (搜索) (HIF-2α (搜索)) inhibitor, marks the 17th global approval for this indication, providing a systemic therapy option for Chinese patients.
The National Medical Products Administration (NMPA) in China has granted approval to MSD's Welireg (belzutifan), an oral hypoxia-inducible factor-2 alpha (搜索) (HIF-2α (搜索)) inhibitor, for the treatment of adult patients with specific types of von Hippel-Lindau (VHL) disease-associated tumors. This approval targets renal cell carcinoma (搜索) (RCC), central nervous system (CNS) hemangioblastomas, and pancreatic neuroendocrine tumors (搜索) (pNET) that do not necessitate immediate surgery.
The approval is grounded in the outcomes of the Phase II LITESPARK-004 trial, which assessed objective response rate (ORR) and median duration of response (DOR). This marks the 17th global approval for Welireg for this indication. The U.S. Food and Drug Administration approved Welireg in August 2021 for similar indications.
LITESPARK-004 Trial Results
The open-label LITESPARK-004 trial involved 61 participants with VHL-associated RCC. The results showed an ORR of 49%, with all responses being partial responses. The median DOR was not reached, with ongoing responses ranging from 2.8 to over 22 months.
Patients with VHL-associated CNS hemangioblastomas demonstrated an ORR of 63%, comprising a 4% complete response rate and a 58% partial response rate. For individuals with VHL-associated pNET, the ORR was 83%, including a 17% complete response rate and a 67% partial response rate.
Expert Commentary
Dr. Marjorie Green, head of oncology, global clinical development, and senior vice-president at MSD research laboratories, stated, "This approval of WELIREG brings the first and only systemic therapy to adult patients in China with certain VHL disease-associated tumours who, to date, have not had access to a non-surgical treatment option to help manage manifestations of VHL disease."
Further Development
Welireg has previously been approved in the US for treating adult patients with advanced RCC following treatment with a programmed death receptor-1 (PD-1 (搜索)) or programmed death-ligand 1 (PD-L1 (搜索)) inhibitor and a vascular endothelial growth factor-tyrosine kinase inhibitor (VEGF-TKI (搜索)), based on the Phase III LITESPARK-005 trial results.
MSD is actively evaluating Welireg in advanced RCC and other tumor types through an extensive clinical development program, including Phase II and III trials, both as a monotherapy and in combination with other medications.